Plerixafor dosing and administration in a patient with dialysis-dependent renal failure

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 2028-2030

  Gregory, Kelly M ^a   Rao, Kamakshi V ^a,b   Armistead, Paul M ^a,c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dosing; Hemodialysis; Multiple myeloma; Plerixafor; Renal dysfunction

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PLERIXAFOR;

ABSENCE OF SIDE EFFECTS; ADULT; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; DIALYSIS; DRUG MEGADOSE; ENGRAFTMENT; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; COMBINED MODALITY THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MULTIPLE MYELOMA; RECEPTORS, CXCR4; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 78649956454     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P223     Document Type: Article

References (11)

1. Product information. Mozobil (plerixafor). Cambridge, MA: Genzyme, December 2008.
2. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
3. DiPersio JF, Micallef I, Stiff PJ, et al. Phase III prospective randomized double-blind placebo controlled trial of plerixafor plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73.
4. MacFarland R, Hard ML, Scarborough R, et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant 2010;16:95-101.
5. Douglas KW, Hayden PJ, O'Dwyer ME, et al. Plerixafor plus G-CSF is effective without significant toxicity in PBSC mobilization from myeloma patients with dialysis-dependent renal failure who have failed to mobilize by conventional means: an initial series of three patients (abstract 600). Presented at: The 35th Annual Meeting of the European Group for Blood and Marrow Transplantation, Göteborg, Sweden, March 30, 2009.
6. Pusic I, DiPersio JF. The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des 2008;14:1950-61.
7. Alexanian R, Barlogie B, Dixon D, et al. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990;150:1693-5.
8. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28-36.
9. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56.
10. Milone G, Leotta S, Indelicato F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 2003; 31:747-54.
11. Stewart DA, Smith C, MacFarland R, et al. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009;15:39-46.